7
Participants
Start Date
March 13, 2023
Primary Completion Date
September 24, 2025
Study Completion Date
September 24, 2025
fordadistrogene movaparvovec
gene therapy administered in a previous study.
Duke Lenox Baker Children's, Durham
Duke Children's Health Center, Durham
University of Utah Imaging and Neurosciences Center, Salt Lake City
University of Utah Hospital, Salt Lake City
Primary Children's Hospital, Salt Lake City
University of Utah Clinical Neurosciences Center, Salt Lake City
University of Utah Craig H. Neilsen Rehabilitation Hospital, Salt Lake City
Reed Neurological Research Center, Los Angeles
UCLA Children's Heart Center, Los Angeles
UCLA Clinical Lab Services, Los Angeles
UCLA Kameron Gait and Motion Analysis Laboratory (Westwood Rehabilitation Center), Los Angeles
UCLA Medical Center, Los Angeles
Lead Sponsor
Pfizer
INDUSTRY